Peptides
The Next GLP-1: Orforglipron Brings Pill-Form, Non-Peptide Receptor Agonism
A 26-week Phase 2 trial pits a once-daily oral non-peptide against dulaglutide — and the β-cell and insulin-sensitivity signals are hard to ignore.
peptides
Peptides
GLP-1s Beyond Blood Sugar: The Quiet Case for Organ Preservation
The same peptide class that reshaped weight loss is now stacking evidence in kidney protection, fibrosis prevention, and transplant medicine. Here's what the data actually says.
Peptides
GLP-1s Keep Surprising Us: New Signals on Asthma, the Heart, and a Strange Ear Problem
The same drugs reshaping body composition are now generating clinical surprises in both directions — including a side effect nobody saw coming.
Peptides
GLP-1 Drugs Get a Reality Check: What Tirzepatide, Semaglutide, and Liraglutide Are Actually Doing
A wave of 2025 analyses is dissecting the real mechanisms behind the headline weight loss — and the picture is messier, smarter, and more interesting than the marketing.
Peptides
Semaglutide's Expanding Reach: From Waistlines to Kidneys, Liver, and Brain
GLP-1 receptor agonists keep finding new organs to help. A fresh slate of 2025 evidence maps where the signal is strongest — and where it's still preliminary.
Peptides
GLP-1s Beyond Glucose: Liver, Plaque, and a Pancreas Warning Shot
Semaglutide, exendin-4, and tirzepatide are pushing GLP-1 receptor agonists into hepatology and cardiology — while a fresh case report reminds us the safety ledger is still open.
Peptides
The New Peptide Pipeline: How AI Is Quietly Rewiring Drug Discovery
Computational design is pushing peptide therapeutics into oncology, infectious disease, and antimicrobial resistance. The early signals are real — and the caveats matter.
Peptides
GLP-1s Go Cardio: What a New Meta-Analysis Says About Heart Attack Risk
A 109,000-patient meta-analysis sharpens the case that GLP-1 receptor agonists are cardiometabolic drugs, not just weight-loss tools — with concrete numbers on who actually benefits.
Peptides
GLP-1's Expanding Frontier: Type 1 Modeling and the Brown-Fat PET Surprise
GLP-1 receptor agonists keep pushing into new clinical territory. Two 2025 papers — a modeling review for type 1 diabetes and a case report where semaglutide lit up brown fat on a PET scan — hint at what's next.
Peptides
Beyond Weight Loss: GLP-1 Agonists Push Into Addiction Medicine and Vascular Repair
Semaglutide and liraglutide are being studied well past their metabolic origins. Early signals point to alcohol use disorder and diabetic blood-vessel protection — but the evidence is still uneven.